Futibatinib

Futibatinib

Clinical data
Trade names	Lytgobi
Other names	TAS-120
AHFS/Drugs.com	Micromedex Detailed Consumer Information
License data	US DailyMed: Futibatinib
Routes of administration	By mouth
Drug class	Antineoplastic
ATC code	L01EN04 (WHO)
Legal status
Legal status	US: ℞-only
Identifiers
IUPAC name 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]prop-2-en-1-one
CAS Number	1448169-71-8
PubChem CID	71621331
IUPHAR/BPS	9786
DrugBank	DB15149
ChemSpider	58877816
UNII	4B93MGE4AL
KEGG	D11725
ChEMBL	ChEMBL3701238
PDB ligand	TZ0 (PDBe, RCSB PDB)
Chemical and physical data
Formula	C22H22N6O3
Molar mass	418.457 g·mol−1
3D model (JSmol)	Interactive image
SMILES COC1=CC(=CC(OC)=C1)C#CC1=NN([C@H]2CCN(C2)C(=O)C=C)C2=C1C(N)=NC=N2
InChI InChI=1S/C22H22N6O3/c1-4-19(29)27-8-7-15(12-27)28-22-20(21(23)24-13-25-22)18(26-28)6-5-14-9-16(30-2)11-17(10-14)31-3/h4,9-11,13,15H,1,7-8,12H2,2-3H3,(H2,23,24,25)/t15-/m0/s1 Key:KEIPNCCJPRMIAX-HNNXBMFYSA-N

Futibatinib, sold under the brand name Lytgobi, is an anti-cancer medication used for the treatment of cholangiocarcinoma (bile duct cancer). It is a kinase inhibitor. It is taken by mouth.

Futibatinib was approved for medical use in the United States in September 2022.

Medical uses

Futibatinib is indicated for the treatment of adults with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.

Society and culture

Legal status

On 26 April 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product Lytgobi, intended for the second-line treatment of locally advanced or metastatic cholangiocarcinoma characterized by fusion or rearrangements of fibroblast growth factor receptor (FGFR) 2. The applicant for this medicinal product is Taiho Pharma Netherlands B.V.

Names

Futibatinib is the international nonproprietary name (INN).